BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 20026115)

  • 21. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells.
    Zhu ML; Kyprianou N
    FASEB J; 2010 Mar; 24(3):769-77. PubMed ID: 19901020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.
    Ji Q; Liu X; Han Z; Zhou L; Sui H; Yan L; Jiang H; Ren J; Cai J; Li Q
    BMC Cancer; 2015 Mar; 15():97. PubMed ID: 25884904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells.
    Bartscht T; Lehnert H; Gieseler F; Ungefroren H
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):221-30. PubMed ID: 22699812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Twist1-induced epithelial-mesenchymal transition according to microsatellite instability status in colon cancer cells.
    Oh BY; Kim SY; Lee YS; Hong HK; Kim TW; Kim SH; Lee WY; Cho YB
    Oncotarget; 2016 Aug; 7(35):57066-57076. PubMed ID: 27494849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activin type 2 receptor restoration in MSI-H colon cancer suppresses growth and enhances migration with activin.
    Jung BH; Beck SE; Cabral J; Chau E; Cabrera BL; Fiorino A; Smith EJ; Bocanegra M; Carethers JM
    Gastroenterology; 2007 Feb; 132(2):633-44. PubMed ID: 17258738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Syntenin regulates TGF-β1-induced Smad activation and the epithelial-to-mesenchymal transition by inhibiting caveolin-mediated TGF-β type I receptor internalization.
    Hwangbo C; Tae N; Lee S; Kim O; Park OK; Kim J; Kwon SH; Lee JH
    Oncogene; 2016 Jan; 35(3):389-401. PubMed ID: 25893292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Src activation is not necessary for transforming growth factor (TGF)-beta-mediated epithelial to mesenchymal transitions (EMT) in mammary epithelial cells. PP1 directly inhibits TGF-beta receptors I and II.
    Maeda M; Shintani Y; Wheelock MJ; Johnson KR
    J Biol Chem; 2006 Jan; 281(1):59-68. PubMed ID: 16267045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of dihydrotestosterone (DHT) on TGF-β1 signaling pathway in epithelial ovarian cancer cells.
    Kohan-Ivani K; Gabler F; Selman A; Vega M; Romero C
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):47-58. PubMed ID: 26091707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutations of transforming growth factor beta 1 type II receptor, BAX, and insulin-like growth factor II receptor genes in microsatellite unstable cell lines.
    Carethers JM; Pham TT
    In Vivo; 2000; 14(1):13-20. PubMed ID: 10757056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis.
    Han G; Lu SL; Li AG; He W; Corless CL; Kulesz-Martin M; Wang XJ
    J Clin Invest; 2005 Jul; 115(7):1714-23. PubMed ID: 15937546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The metastasis suppressor CD82/KAI1 represses the TGF-β
    Lee MS; Lee J; Kim YM; Lee H
    Prostate; 2019 Sep; 79(12):1400-1411. PubMed ID: 31212375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simvastatin attenuates TGF-β1-induced epithelial-mesenchymal transition in human alveolar epithelial cells.
    Yang T; Chen M; Sun T
    Cell Physiol Biochem; 2013; 31(6):863-74. PubMed ID: 23817018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular mechanism of miR-153 inhibiting migration, invasion and epithelial-mesenchymal transition of breast cancer by regulating transforming growth factor beta (TGF-β) signaling pathway.
    Wang J; Liang S; Duan X
    J Cell Biochem; 2019 Jun; 120(6):9539-9546. PubMed ID: 30525231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors.
    Ungefroren H; Sebens S; Groth S; Gieseler F; Fändrich F
    Curr Cancer Drug Targets; 2011 May; 11(4):524-35. PubMed ID: 21395548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin-like growth factor-binding protein-3 promotes transforming growth factor-{beta}1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells.
    Natsuizaka M; Ohashi S; Wong GS; Ahmadi A; Kalman RA; Budo D; Klein-Szanto AJ; Herlyn M; Diehl JA; Nakagawa H
    Carcinogenesis; 2010 Aug; 31(8):1344-53. PubMed ID: 20513670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The relationship between frameshift mutations of transforming growth factor-beta type II receptor, insulin growth factor II receptor, bcl-2 associated X protein, E2F4 and microsatellite instability in gastric carcinoma].
    Chen GT; Zhu ZG; Yin HR; Liu BY; Ji J; Zhang J; Lin YZ
    Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(5):344-8. PubMed ID: 16635398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo and in vitro evidence for transforming growth factor-beta1-mediated epithelial to mesenchymal transition in esophageal adenocarcinoma.
    Rees JR; Onwuegbusi BA; Save VE; Alderson D; Fitzgerald RC
    Cancer Res; 2006 Oct; 66(19):9583-90. PubMed ID: 17018615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation of three new mouse mammary tumor cell lines as models for transforming growth factor (TGF)-beta and Neu pathway signaling studies: identification of a novel model for TGF-beta-induced epithelial-to-mesenchymal transition.
    Lenferink AE; Magoon J; Cantin C; O'Connor-McCourt MD
    Breast Cancer Res; 2004; 6(5):R514-30. PubMed ID: 15318933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transforming growth factor-β 1 enhances the invasiveness of breast cancer cells by inducing a Smad2-dependent epithelial-to-mesenchymal transition.
    Lv ZD; Kong B; Li JG; Qu HL; Wang XG; Cao WH; Liu XY; Wang Y; Yang ZC; Xu HM; Wang HB
    Oncol Rep; 2013 Jan; 29(1):219-25. PubMed ID: 23129177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-beta receptor III.
    Yan Z; Deng X; Friedman E
    J Biol Chem; 2001 Jan; 276(2):1555-63. PubMed ID: 11029459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.